Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.42 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | CDA | P32320 | 6/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17972130 | 1.00 | SLC29A1 (0.43) | SLC29A1PDE4DPDE3AP2RY6P2RY2 | |
| SCHEMBL20427385 | 0.88 | SLC29A1 (0.55) | SLC29A1PDE4DPDE3AP2RY6P2RY2 | |
| SCHEMBL17972124 | 0.88 | SLC29A1 (0.40) | SLC29A1PDE4DPDE3AP2RY6P2RY2 | |
| SCHEMBL16576343 | 0.88 | SLC29A1 (0.40) | SLC29A1PDE4DPDE3AP2RY6P2RY2 | |
| SCHEMBL24371643 | 0.86 | P2RY2 (0.42) | SLC29A1PDE4DPDE3AP2RY6P2RY2 | |
| SCHEMBL17972174 | 0.86 | P2RY2 (0.42) | SLC29A1PDE4DPDE3AP2RY6P2RY2 | |
| SCHEMBL16575775 | 0.86 | P2RY2 (0.42) | SLC29A1PDE4DPDE3AP2RY6P2RY2 | |
| SCHEMBL18069637 | 0.86 | P2RY2 (0.42) | SLC29A1PDE4DPDE3AP2RY6P2RY2 | |
| SCHEMBL17972122 | 0.85 | SLC29A1 (0.44) | SLC29A1PDE4DPDE3AP2RY6P2RY2 | |
| SCHEMBL21418660 | 0.85 | SLC29A1 (0.44) | SLC29A1PDE4DPDE3AP2RY6P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| WO-2015038596-A1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | SLC29A1 15/4885PDE4D 1445/4885PDE3A 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.